戻る 戻る
細胞番号 : 細胞名
RCB1640 : DAUDI  update : 2024/01/17
細胞特性(Comment:英)Burkitt's lymphoma. Sensitive to lymphokine-activated killer cells but resistant to natural killer cells. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011437 prior to order.
細胞特性(日)ヒトバーキットリンパ腫。ECACC由来株。使用条件等がECACCによって随時変更となる可能性があります。ご購入前に、ECACC 85011437 を必ずご参照ください。
使用条件(英)1) There is no restriction regarding use for basic researches. However, since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECA85011437 prior to order. 2) In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)1) 基礎的研究につきましては、使用制限はありません。しかし、使用条件等がECACCによって随時変更となる可能性があるので、購入前に、ECA85011437 を必ず参照すること。2) 商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 ECACC
寄託日 2000
動物種 _human < Mammals
属名 Homo
種名 sapiens
人種 Negloid
性別 Male
16 years
採取組織 blood
病名 Burkitt's lymphoma
細胞分類 cancer
入手歴 overseas, ECACC -> RIKEN Cell Bank
細胞寿命 infinite
細胞形態 lymphocyte-like
Cellosaurus(Expasy) CVCL_0008
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Suspension cells
培地 RPMI1640 + 10% FBS
培養方法 浮遊細胞の培養に関する一般的な注意
抗生物質 Free
継代方法 dilution
継代密度 1 : 10 split
継代・培地交換頻度 Subculture : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
ウィルス(HIV) LT 400
ウィルス(HTLV-1) (-)
ウィルス(EBV) (+)
アイソザイム検査 LD, NP
染色体検査 46-47(50) : 46(10),48(40)
個体識別検査 OK
文献情報 Reference(英) 6件
Reference(日) 0件
利用者成果(英) 12件
利用者成果(日) 0件

5042  Haruta Y, Seon BK.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.  Proc Natl Acad Sci U S A  1986  83(20):7898-902  PubMed ID: 3464004   DOI: 10.1073/pnas.83.20.7898
2417  Nilsson K, Giovanella, B C, Stehlin, J S, Klein G  Tumorigenicity of human hematopoietic cell lines in athymic nude mice.  Int J Cancer  1977  19:337-44  PubMed ID: 14896   DOI: 10.1002/ijc.2910190309
1141  Ralph P, Moore, M A, Nilsson K  Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.  J Exp Med  1976  143:1528-33  PubMed ID: 1083890   DOI: 10.1084/jem.143.6.1528
4975  Neumann H, Klein E, Hauck-Granoth R, Yachnin S, Ben-Bassat H.  Comparative study of alkaline phosphatase activity in lymphocytes, mitogen-induced blasts, lymphoblastoid cell lines, acute myeloid leukemia, and chronic lymphatic leukemia cells.  Proc Natl Acad Sci U S A  1976  73(5):1432-6  PubMed ID: 1064015   DOI: 10.1073/pnas.73.5.1432
971  Klein E, Klein G, Nadkarni, J S, Nadkarni, J J, Wigzell H, Clifford P  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.  Cancer Res  1968  28:1300-10  PubMed ID: 4174339  
2416  Klein E, Klein G, Nadkarni, J S, Nadkarni, J J, Wigzell H, Clifford P  Surgace IgM specificity on cells derived from a Burkitt's lymphoma.  Lancet  1967  2:1068-70  PubMed ID: 4168541   DOI: 10.1016/s0140-6736(67)90340-6


16945  Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.  Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy  Cancer Sci  2022  113(6):2129-2143  PubMed ID: 35343027   DOI: 10.1111/cas.15349
13229  Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J.  Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.  J Immunother Cancer  2020    PubMed ID: 32948652   DOI: 10.1136/jitc-2020-001185
5030  Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita YI, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T, Arima K, Okabe H, Baba Y, Chikamoto A, Ishiko T, Hirota M, Baba H.  PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.  Cancer Sci  2019  110(1):310-320  PubMed ID: 30426611   DOI: 10.1111/cas.13874
10069  Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M.  PD-L1 expression in papillary renal cell carcinoma.  BMC Urol  2017  17:8  PubMed ID: 28086852   DOI: 10.1186/s12894-016-0195-x
10269  Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.  Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages  J Clin Exp Hematop  2017  57:15-20  PubMed ID: 28420814   DOI: 10.3960/jslrt.17003
13994  Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y.  An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma  Cancer Sci  2016  107(11):1696-1704  PubMed ID: 27564404   DOI: 10.1111/cas.13065
14309  Ninomiya S, Kawano M, Abe T, Ishikawa T, Takahashi M, Tamura M, Takahashi Y, Nashimoto M.  Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines  PLoS One  2015  10(3):e0118631  PubMed ID: 25730316   DOI: 10.1371/journal.pone.0118631
13727  Goto H, Matsuda K, Srikoon P, Kariya R, Hattori S, Taura M, Katano H, Okada S.  Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma  Cancer Lett  2013  331(2):174-82  PubMed ID: 23321500   DOI: 10.1016/j.canlet.2012.12.021
15339  Bai B, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Takeya M, Komohara Y.  Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study  J Clin Exp Hematop  2013  53(2):127-33  PubMed ID: 23995109   DOI: 10.3960/jslrt.53.127
16574  Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.  Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain  Cytotherapy  2013  15(4):481-91  PubMed ID: 23391461   DOI: 10.1016/j.jcyt.2012.12.004
2320  Kim C, Matsumura M, Saijo K, Ohno T.  In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.  Cancer Immunol Immunother.  1998  47(2):90-6  PubMed ID: 9769117   DOI: 10.1007/s002620050508
2318  Liu SQ, Kawai K, Shiraiwa H, Hayashi H, Akaza H, Hashizaki K, Shiba R, Saijo K, Ohno T.  High rate of induction of human autologous cytotoxic T lymphocytes against renal carcinoma cells cultured with an interleukin cocktail.  Jpn J Cancer Res  1998  89(11):1195-201  PubMed ID: 9914789   DOI: 10.1111/j.1349-7006.1998.tb00515.x


戻る 戻る 理研トップページへ